University of Florida Research Foundation, Incorporated

Duke University

University of California

University of Pennsylvania

Taiho Pharmaceutical Company Limited

Biomolecular Research Institute Ltd.

Bachem Bioscience, Ing.

Kempharm Consulting Inc.

William Reade Kem

Ferenc Soti

John A Zoltewicz

Edwin M Meyer

Roger Lee Papke

Dan Rittschof

Hong Xing

Makoto Kajitani

K George Chandy

Michael William Pennington

Raymond Stanley Norton

Kazuo Maruhashi

Jon Lindstrom

Katalin Kalman

Adriaan Willem Bruijnzeel

Katalin Prokai-Tatrai

Sara Jo Nixon

Hun Ju Lee

Syotaro Watanabe

Christopher M De Fiebre

Anne Rouchaud

Franz Van Haaren

Arthur Day

Kristin Marie Andrud

Embodiments of the present disclosure provide for compounds such as those shown in FIG.(compounds A, B, C, and D), 2'substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG., compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2&#x2032;substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like. 

Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use

Briefly described, embodiments of this disclosure, among others, include compositions, pharmaceutical compositions, methods of treating nicotine dependence, methods of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorder, method of treating a subject who smokes and has a risk for depression or other neuropsychiatric disorders, and the like.

Compositions, methods of use, and methods of treatment

The invention relates to the design and synthesis of novel anabaseine-based compounds, which are useful in treating or preventing a wide variety of conditions, including nervous system diseases or disorders, such as, schizophrenia, Alzheimer's disease, Parkinson's disease, drug dependence, and substance addiction, and compositions, kits, and methods thereof. The invention also provides novel anabaseine-based compounds, compositions, kits, and methods thereof for treating or preventing non-nerve system diseases or disorders (such as, inflammation and cancer) in a subject identified in need thereof. Certain enantiomeric compounds of the invention exhibited enhanced selectivity toward &#x3b1;7 nAChRs relative to alpha4beta2 nAChRs. Other enantiomeric compounds of the invention exhibited enhanced selectivity for alpha4beta2 nAChRs relative to &#x3b1;7 nAChRs.

Nicotine receptor targeted compounds and compositions

The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations mediated by macrophage infiltration.

Alpha7 nicotinic receptor selective ligands

Alpha 7 nicotinic receptor selective ligands

The subject invention provides materials and methods for inhibiting the biofouling of surfaces exposed to aquatic environments. In one embodiment, the subject invention provides additives for marine paints and surface treatments. The subject invention further provides repellents and selective inhibitors for aquatic and/or terrestrial crustacean pests.

Materials and methods for inhibiting fouling of surfaces exposed to aquatic environments

The subject invention provides materials and methods for inhibiting the biofouling of surfaces exposed to aquatic environments. In one embodiment, the subject invention provides additives for marine paints and surface treatments. The subject invention further provides repellants and selective inhibitors for aquatic and/or terrestrial crustacean pests.

Method of using anabaseine, DMAB-anabaseine, and anabaseine for stimulating brain cholinergic transmission and a method of making anabaseine.

Use of nicotinic analogs for treatment of degenerative diseases of the nervous system

Disclosed are methods and compositions comprising DNA segments, and proteins derived from sea anemone species. More particularly, it concerns the novel ShK toxin, ShK toxin analogs, chemically-modified toxin analogs, and nucleic acid segments encoding the ShK toxin from Stichodactyla helianthus. Various methods for making and using these DNA segments, DNA segments encoding synthetically-modified ShK toxins, and native and synthetic ShK peptides are disclosed, such as, for example, the use of DNA segments as diagnostic probes and templates for protein production, and the use of proteins, fusion protein carriers and peptides in various immunological and diagnostic applications.

ShK toxin compositions and methods of use

This invention relates to compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the alpha7 receptor subtype with little or no activation of the alpha4beta2 or other receptor subtypes.

Methods of use and compositions for benzylidene- and

Anabaseine derivatives useful in the treatment of degenerative diseases

Production intermediate and process for producing pyridine derivative

Use of nicotinic analogs for treatment of degenerative diseases of the

Growing community of inventors

Gainesville, FL, United States of America

William Reade Kem